PMC, the Personalized Medicine Coalition, announced that George Poste, DVM, PhD, Regents Professor and Del E. Webb Chair in Health Innovation and Chief Scientist, Complex Adaptive Systems Initiative at Arizona State University, will receive the 2025 Award for Leadership in Personalized Medicine at this year’s Personalized Medicine Conference, to be held November 13–14 at the Ritz Carlton, Laguna Niguel, in Dana Point, California. This award recognizes Dr. Poste’s substantial multi-decade contributions to the advancement of personalized medicine and his enduring impact on science, technology, and policy.
Image Source: PMC/LinkedIn
A globally respected leader in biomedical innovation, Dr. Poste has made seminal contributions to our understanding of personalized medicine, especially related to tumor heterogeneity and the development of targeted drug delivery systems. As President of R&D at SmithKline Beecham in the 1990s he pioneered the adoption of large-scale genomics in the pharmaceutical industry. He has served on the boards of multiple biotechnology companies, including a foundational role in launching Caris Life Sciences, a company at the forefront of precision oncology combining multiOmics technologies, digital pathology and AI.
In addition to his scientific achievements in drug and diagnostics development, Dr. Poste has served on high-impact policy and advisory bodies including the UK Human Genetics Advisory Committee, creation of the UK Biobank, the U.S. Defense Science Board, the National Academies Forum on Microbial Threats, Bipartisan Commission on Biodefense and the World Economic Forum Board of Medical Governors. He is a member of the UK Royal Society and in recognition of his leadership in the biotechnology and pharmaceutical industries, he was named a Commander of the British Empire (CBE) by Queen Elizabeth II.
Dr. Poste’s remarkable career and contributions to the field will be recognized on the first day of this year’s Annual Personalized Medicine Conference on November 13, 2025 in Dana Point, California.
Following the award presentation, Dr. Poste will deliver the keynote address and share his perspectives on challenges and opportunities for the next era of precision health.
Previous recipients of Award for Leadership in Personalized Medicine include among others:
- Dr. Francis S. Collins, M.D., Ph.D., (former Director, U.S. National Institutes of Health)
- Dr. Janet Woodcock, M.D., (former Director, U.S. Food and Drug Administration, Center for Drug Evaluation and Research)
- Dr. Carl H. June, M.D., (University of Pennsylvania and pioneer of CAR-T Cancer Immunotherapy)
- Dr. Leroy Hood, Ph.D., M.D., (President, Institute for Systems Biology and multiOmics pioneer)
- Dr. William S. Dalton, Ph.D., M.D., CEO, (Director Moffitt Cancer Center)
- Jay T. Flatley, (CEO, Illumina)
- Dr. Ellen V. Sigal, Ph.D., (Founder, Friends of Cancer Research and 21st Century Cures Act)
- Michael O. Leavitt, (U.S. Secretary, Department of Health and Human Services)
- Brook Byers, (Managing Partner, Kleiner Perkins Caufield & Byers and long-time leading venture capitalist in the growth of the biotechnology industry)
- Kathy Giusti, (CEO, Multiple Myeloma Research Foundation)
The honoree is selected annually by the PMC Bord of Directors.
PMC comprises over 200 active members which includes universities, academic medical centers, healthcare providers, payers, biopharmaceutical and information technology companies, regulators and officials (ex-officio) from multiple USG agencies. Working groups that draw upon PMC membership publish a series of highly influential papers each year on policy issues and participation in congressional hearings related to technology innovation, regulation and reimbursement issues in precision health.